Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TCRT

Alaunos Therapeutics, Inc.

Healthcare | Biotechnology
$1.92
Volume912
EPS (TTM)$-1.90

Alaunos Therapeutics, Inc. (NASDAQ: TCRT) is a biotechnology company trading at $1.92. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:44 UTC.

What Alaunos Therapeutics, Inc. does

The company is a preclinical-stage biopharmaceutical developer focused on creating orally administered small-molecule treatments for obesity and related metabolic disorders, including a fatty liver disease called MASLD, using a non-hormonal approach different from GLP-1 drugs. The company previously operated as an oncology cell therapy company but has transitioned its focus and has not generated any product revenue.

Summarized from Alaunos Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$1.92
Volume912 shares
Valuation
EPS (TTM)$-1.90

Revenue, margins & earnings

FY2021: net loss $79M on revenue $398,000$398,000FY2021FY2022: net loss $38M on revenue $3M$3MFY2022FY2023: net loss $5M on revenue $5,000$5,000FY2023FY2024: net loss $5M on revenue $10,000$10,000FY2024FY2025: net loss $4M on revenue $5,000$5,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-08
  • 2026-10-08DirectorAward22,669$16.9K
  • 2026-10-08CEOAward23,564$17.5K
  • 2026-10-08DirectorAward21,829$16.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Alaunos Therapeutics, Inc. do?

The company is a preclinical-stage biopharmaceutical developer focused on creating orally administered small-molecule treatments for obesity and related metabolic disorders, including a fatty liver disease called MASLD, using a non-hormonal approach different from GLP-1 drugs.

What is TCRT's valuation?

TCRT trades at $1.92, as of 2026-10-11.

When did TCRT last file with the SEC?

Alaunos Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:44 UTC. This page is also available as JSON at /api/data?ticker=TCRT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TCRT and 5,000+ tickers.

Create a free account — keep TCRT
For your agent
GET /api/data?ticker=TCRT

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt